Current Report Filing (8-k)
July 12 2017 - 5:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): July 11, 2017
RICH
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
NEVADA
|
|
000-54767
|
|
46-3259117
|
(State
or other jurisdiction of
incorporation or organization)
|
|
Commission
file number
|
|
(IRS
Employer
Identification
No.)
|
9595
Wilshire Blvd, Suite 900
Beverly
Hills, CA 90212
(Address
of principal executive offices)
(424)
230-7001
(Registrant’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
◻
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
◻
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
◻
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
◻
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item
1.01
|
Entry
Into a Material Definitive Agreement.
|
On
July 11, 2017, Rich Pharmaceuticals, Inc. (the “Company”) entered into a Support and Collaboration Agreement (the
“Collaboration Agreement”) with Mega Bridge, Inc., a Nevada corporation to be renamed “Hypgen”) (“Hypgen”),
to support Hypgen’s development of treatments for Parkinson’s Disease. Under the terms of the agreement, the Company
will provide data, raw materials and advisory support to Hypgen to assist Hypgen with their development of treatments for Parkinson’s
Disease and the associated regulatory approval process. In exchange, Hypgen will pay the Company $100,000 and issue the Company
15,000,000 shares of Hypgen common stock. The Company plans to dividend five million of these shares to its shareholders at such
time as the Company completes the necessary corporate and regulatory requirements regarding payment of a dividend. The foregoing
is only a brief description of the material terms of the Collaboration Agreement and does not purport to be a complete description
of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to
the agreements and their exhibits which are filed as an exhibit to this Current Report.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
RICH
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
Dated:
July 12, 2017
|
|
|
|
By:
|
|
/s/ Ben
Chang
|
|
|
|
|
|
|
|
|
Ben
Chang
Chief
Executive Officer
|